Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MONIKA MOHAN

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1295852895
CMS profile
286018
Location
OKEMOS, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$10,248.36

173 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 173 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MONIKA MOHAN

NPI 1295852895 · CMS profile ID 286018

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

OKEMOS, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 173 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1295852895?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MONIKA MOHAN, NPI 1295852895, CMS profile ID 286018. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 173 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1295852895?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MONIKA MOHAN, NPI 1295852895, CMS profile ID 286018. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 173 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1295852895?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MONIKA MOHAN, NPI 1295852895, CMS profile ID 286018, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 173 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1295852895?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

173 matching records · $10,248.36 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 173 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 173.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Biotech, Inc. $3.5505/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078759042 CMS
Novartis Pharmaceuticals Corporation $17.5805/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086961374 CMS
Amgen Inc. $9.3405/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115939263 CMS
Janssen Biotech, Inc. $3.7705/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078759128 CMS
UCB, Inc. $35.4505/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143335328 CMS
Radius Health, Inc. $14.4105/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089978016 CMS
Amgen Inc. $25.5804/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115939210 CMS
Janssen Biotech, Inc. $15.7304/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078759005 CMS
Alvogen Inc $16.3304/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137625067 CMS
Novartis Pharmaceuticals Corporation $28.2704/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086961372 CMS
Janssen Biotech, Inc. $7.2904/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078759062 CMS
PFIZER INC. $15.9104/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131712950 CMS
AstraZeneca Pharmaceuticals LP $15.1904/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105866312 CMS
PFIZER INC. $1.7704/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132050990 CMS
ABBVIE INC. $3.6704/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105051584 CMS
Amgen Inc. $20.5804/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115939230 CMS
Janssen Biotech, Inc. $11.2604/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078759240 CMS
Novartis Pharmaceuticals Corporation $12.5504/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086961370 CMS
Amgen Inc. $2,430.0003/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117632121 CMS
Amgen Inc. $405.0003/25/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117632123 CMS
Amgen Inc. $723.6003/25/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117632125 CMS
Fidia Pharma USA Inc. $20.6703/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141158221 CMS
Amgen Inc. $23.4303/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117632115 CMS
Amgen Inc. $113.8203/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117632117 CMS
AstraZeneca Pharmaceuticals LP $15.4903/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104241245 CMS
Amgen Inc. $2,025.0003/18/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117632119 CMS
ABBVIE INC. $21.0803/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105051582 CMS
ABBVIE INC. $12.3003/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105051576 CMS
ABBVIE INC. $4.5903/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105051578 CMS
ABBVIE INC. $1.7403/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105051580 CMS
UCB, Inc. $0.8003/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143335307 CMS
UCB, Inc. $0.9903/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143335311 CMS
UCB, Inc. $3.9003/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143335315 CMS
UCB, Inc. $4.0503/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143335320 CMS
UCB, Inc. $4.3403/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143335324 CMS
Amgen Inc. $25.5203/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117632133 CMS
ABBVIE INC. $18.3903/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105051574 CMS
E.R. Squibb & Sons, L.L.C. $15.0803/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101415469 CMS
AstraZeneca Pharmaceuticals LP $14.8203/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105261918 CMS
ABBVIE INC. $3.6903/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105051572 CMS
Janssen Biotech, Inc. $13.4203/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078758862 CMS
Janssen Biotech, Inc. $10.1403/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078758626 CMS
UCB, Inc. $21.5303/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143335303 CMS
Amgen Inc. $17.6102/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115939224 CMS
Janssen Biotech, Inc. $3.4402/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078759287 CMS
Organon Llc $15.7302/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136213531 CMS
Lilly USA, LLC $24.9702/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135222302 CMS
Aurinia Pharma U.S., Inc. $15.4302/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150687719 CMS
ABBVIE INC. $20.4902/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105051570 CMS
Novartis Pharmaceuticals Corporation $27.6402/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086961368 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $73,858.47 260
PY2020 $21,296.03 113
PY2021 $1,960.01 141
PY2022 $3,199.14 133
PY2023 $10,465.61 143
PY2024 $10,248.36 173
PY2025 $6,017.99 177

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $149,003.87 73
PY2024 Recipient $114.46 1
PY2024 Principal investigator $121,110.38 33
PY2023 Principal investigator $116,526.50 26
PY2022 Recipient $79.00 1
PY2022 Principal investigator $244,399.27 62
PY2021 Principal investigator $367,860.33 46
PY2020 Recipient $421.40 3
PY2020 Principal investigator $254,269.21 60
PY2019 Principal investigator $236,060.88 47

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

73 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,952.99 12/17/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223289896
Principal investigator 1 ABBVIE INC. $1,319.83 12/04/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202528558
Principal investigator 1 ABBVIE INC. $1,239.90 12/04/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202528560
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,030.30 12/01/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223289128
Principal investigator 1 Janssen Research & Development, LLC $1,942.00 11/27/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233400
Principal investigator 1 Janssen Research & Development, LLC $67.00 11/27/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233518
Principal investigator 1 Janssen Research & Development, LLC $67.00 11/27/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233529
Principal investigator 1 Janssen Research & Development, LLC $2,648.00 11/27/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233600
Principal investigator 1 ABBVIE INC. $46.00 11/04/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202521141
Principal investigator 1 ABBVIE INC. $148.10 10/09/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202516193
Principal investigator 1 ABBVIE INC. $1,096.00 09/22/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202511742
Principal investigator 1 ABBVIE INC. $9,420.00 09/18/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202511386
Principal investigator 1 ABBVIE INC. $487.00 09/11/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202510644
Principal investigator 1 Janssen Research & Development, LLC $400.00 09/08/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233370
Principal investigator 1 Janssen Research & Development, LLC $130.00 09/08/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233468
Principal investigator 1 Janssen Research & Development, LLC $400.00 09/08/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233511
Principal investigator 1 Janssen Research & Development, LLC $100.00 09/08/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233535
Principal investigator 1 Janssen Research & Development, LLC $100.00 09/08/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233642
Principal investigator 1 Janssen Research & Development, LLC $100.00 09/08/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233699
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 09/08/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233750
Principal investigator 1 Janssen Research & Development, LLC $400.00 09/08/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233790
Principal investigator 1 ABBVIE INC. $1,319.83 09/03/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202507443
Principal investigator 1 ABBVIE INC. $2,115.15 09/03/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202507445
Principal investigator 1 ABBVIE INC. $3,000.00 08/05/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202501890
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,514.20 08/01/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223283427
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,940.00 07/01/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223282026
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 07/01/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223282028
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 07/01/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223282030
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $60.00 07/01/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223282032
Principal investigator 1 Janssen Research & Development, LLC $67.00 06/30/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233540
Principal investigator 1 Janssen Research & Development, LLC $1,904.00 06/30/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233816
Principal investigator 1 ABBVIE INC. $1,319.83 06/03/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202487783
Principal investigator 1 ABBVIE INC. $2,011.55 06/03/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202487787
Principal investigator 1 Janssen Research & Development, LLC $67.00 05/28/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233380
Principal investigator 1 Janssen Research & Development, LLC $433.00 05/28/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233424
Principal investigator 1 Janssen Research & Development, LLC $3,318.00 05/28/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233758
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,000.00 05/01/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223278768
Principal investigator 1 ABBVIE INC. $473.50 04/03/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202472865
Principal investigator 1 UCB SA $18,106.00 03/26/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246657636
Principal investigator 1 ABBVIE INC. $3,114.20 03/24/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202465499
Principal investigator 1 Janssen Research & Development, LLC $100.00 03/19/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233481
Principal investigator 1 Janssen Research & Development, LLC $400.00 03/19/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233497
Principal investigator 1 Janssen Research & Development, LLC $100.00 03/19/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233561
Principal investigator 1 Janssen Research & Development, LLC $100.00 03/19/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233607
Principal investigator 1 Janssen Research & Development, LLC $130.00 03/19/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233681
Principal investigator 1 Janssen Research & Development, LLC $100.00 03/19/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233717
Principal investigator 1 Janssen Research & Development, LLC $100.00 03/19/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233774
Principal investigator 1 ABBVIE INC. $522.00 03/13/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202463039
Principal investigator 1 Eli Lilly and Company $34.80 03/10/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187873121
Principal investigator 1 ABBVIE INC. $1,835.75 03/06/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202456493
Principal investigator 1 ABBVIE INC. $1,589.83 03/06/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202456496
Principal investigator 1 Janssen Research & Development, LLC $67.00 02/27/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233634
Principal investigator 1 Janssen Research & Development, LLC $2,171.00 02/27/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233742
Principal investigator 1 Eli Lilly and Company $953.39 02/24/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187880187
Principal investigator 1 UCB SA $61.84 02/24/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246657708
Principal investigator 1 Eli Lilly and Company $26,712.00 02/11/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187871945
Principal investigator 1 ABBVIE INC. $2,107.75 02/05/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202444934
Principal investigator 1 Eli Lilly and Company $8,557.00 02/04/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187874575
Principal investigator 1 Janssen Research & Development, LLC $67.00 01/13/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233414
Principal investigator 1 Janssen Research & Development, LLC $2,185.00 01/13/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233451
Principal investigator 1 Janssen Research & Development, LLC $1,865.00 01/13/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233490
Principal investigator 1 Janssen Research & Development, LLC $67.00 01/13/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233504
Principal investigator 1 Janssen Research & Development, LLC $67.00 01/13/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233575
Principal investigator 1 Janssen Research & Development, LLC $67.00 01/13/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233618
Principal investigator 1 Janssen Research & Development, LLC $67.00 01/13/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233648
Principal investigator 1 Janssen Research & Development, LLC $67.00 01/13/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233768
Principal investigator 1 Janssen Research & Development, LLC $67.00 01/13/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233830
Principal investigator 1 Janssen Research & Development, LLC $67.00 01/13/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233847
Principal investigator 1 Janssen Research & Development, LLC $433.00 01/13/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233865
Principal investigator 1 Janssen Research & Development, LLC $67.00 01/13/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233879
Principal investigator 1 Janssen Research & Development, LLC $3,337.00 01/13/2025 Non-covered Recipient Entity
Advanced Rheumatology
A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX) No dispute reported 06/30/2026 1175233887
Principal investigator 1 ABBVIE INC. $1,319.83 01/02/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202434682
Principal investigator 1 ABBVIE INC. $261.30 01/02/2025 Non-covered Recipient Entity
ADVANCED RHEUMATOLOGY PC
M16-011 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy No dispute reported 06/30/2026 1202434685